Preclinical anti-tumor activity of antibody-targeted chemotherapy with CMC-544 (inotuzumab ozogamicin), a CD22-specific immunoconjugate of calicheamicin, compared with non-targeted combination chemotherapy with CVP or CHOP

Author: DiJoseph John   Dougher Maureen   Evans Deborah   Zhou Bin-Bing   Damle Nitin  

Publisher: Springer Publishing Company

ISSN: 0344-5704

Source: Cancer Chemotherapy and Pharmacology, Vol.67, Iss.4, 2011-04, pp. : 741-749

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content